Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

Boston Scientific Corporation today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.

28 Aug 2009

Ochsner Medical Center selected to participate as an FDA investigative site in the PARTNER clinical trial

On Tuesday, August 11, 2009, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure. Patients who are considered high-risk or non-operable for conventional open heart valve surgery now have a potential new research option available regionally only through The John Ochsner Heart & Vascular Institute.

28 Aug 2009

FBN features Prescient Medical's CEO

Prescient Medical Inc. announced that CEO Patricia Scheller, appeared on FOX Business Network (FBN) to discuss the company's groundbreaking products and recent achievement of CE Mark approval for their vProtect(TM) Luminal Shield Stent System.

27 Aug 2009

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

Medtronic's Q1 financial results announced

Medtronic, Inc. (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2010, which ended July 31, 2009.

25 Aug 2009

First patient enrolled for IDEV Technologies' SUPERB clinical trial

IDEV(R) Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that the first patient was enrolled in the Company's FDA-approved multi-center clinical trial of its self-expanding SUPERA(R) stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD) in the superficial femoral artery (SFA).

25 Aug 2009

New minimally invasive procedure to treat ruptured brain aneurysm developed

Researchers in Finland have identified an effective new treatment option for patients who have suffered a ruptured brain aneurysm, a potentially life-threatening event. Results of the new study on stent-assisted coil embolization were published today in the online edition of Radiology.

25 Aug 2009

Prescient Medical's vProtect(TM) Luminal Shield Stent System receives CE Mark approval for treating heart disorders

Medical device pioneer, Prescient Medical, Inc., announced today that it has received European CE Mark (Conformite Europeene) approval to commercialize its vProtect(TM) Luminal Shield Stent System. The device is now approved for use in improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease.

24 Aug 2009

Micrus Endovascular Corporation and Flexible Stenting Solutions to jointly develop flow diversion technology for neurovascular indications

Micrus Endovascular Corporation and privately held Flexible Stenting Solutions Inc. of Eatontown, N.J., today announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indications using both Micrus and Flexible Stenting Solutions technology, development capabilities and intellectual property.

24 Aug 2009

Endologix publishes abdominal aortic aneurysm treatment trial results online

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today the online publication of results from the pivotal prospective, multicenter clinical trial of the Company's Powerlink XL((R)) System for treatment of abdominal aortic aneurysm in large diameter proximal aortic necks.

21 Aug 2009

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

21 Aug 2009

Scientists grow new blood vessels to combat heart disease

Although open-heart surgery is a frequent treatment for heart disease, it remains extremely dangerous. Now groundbreaking research from Dr. Britta Hardy of Tel Aviv University's Sackler School of Medicine has shown the potential for an injected protein to regrow blood vessels in the human heart ― eliminating the need for risky surgery altogether.

13 Aug 2009

Nfocus Neuromedical obtains CE approval for vascular reconstruction device

Nfocus Neuromedical Inc. announced today that its CardioVasc Advantage Vascular Reconstruction Device has been granted CE Mark approval by the European Notified Body, G-Med.

13 Aug 2009

New drug promises to reduce damage from a heart attack

Research into a new drug by Australian heart experts has found that it can dramatically reduce heart muscle damage after a heart attack.

28 Jul 2009

Deferoxamine could help diabetics heal wounds

A drug used to remove iron from the body could help doctors fight one of diabetes' cruelest complications: poor wound healing, which can lead to amputation of patients' toes, feet and even legs.

28 Jul 2009

New drug may reduce heart attack damage

A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.

22 Jul 2009

J & J: hospital deal will hurt medical device sales

The CFO for Johnson & Johnson's said President Obama's deal with hospitals to cut Medicare costs will reduce the sales of medical devices, Bloomberg reports: "Hospitals buy medical devices, including J&J’s artificial hips and stents to prop open clogged arteries, directly from the manufacturer, (Johnson and Johnson CFO Dominic) Caruso said today in an interview with Bloomberg News.

15 Jul 2009

FDA approves Effient (prasugrel) for heart attack in angioplasty patients

The U.S. Food and Drug Administration has approved the blood-thinning drug Effient tablets (prasugrel) to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery.

12 Jul 2009

AbbeyMoor receives approval for design improvements to ‘The Spanner’ prostatic stent

AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to their flagship product, The Spanner Prostatic Stent.

7 Jul 2009

Diabetes with coronary disease: A moving target amid evolving therapies

In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."

8 Jun 2009